24524-97-8

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 122-51-0 orthoformic acid triethyl ester 
• 104-15-4 toluene-4-sulfonic acid 
• 64-17-5 ethanol 

Downstream Products

• 1188448-07-8 3-(4-fluorophenyl)-8,8-dimethyl-2,2-diphenyl-2,8-dihydrocyclopenta[a]indene 
• 64002-52-4 (4-fluorophenyl)methylene diacetate 
• 83521-64-6 2-(4-fluorophenyl)-1,3-dithiolane 
• 86657-76-3 1-Fluoro-4-(1,3,3-triethoxy-propyl)-benzene 

Relevant academic research and scientific papers

Practical acetalization and transacetalization of carbonyl compounds catalyzed by recyclable PVP-I

A novel PVP-I catalyzed acetalizations/transacetalizations of carbonyl compounds has been developed processing with a mild and easy handling fashion. Different types of Acyclic and cyclic acetals were prepared from carbonyl compounds or their acetals successfully. Further applications of newly developed catalytic combination were testified. This protocol featured with simplicity of operation, mild reaction condition, short reaction time, recyclable of catalyst and broad substrates scope with excellent yields.

Facile synthesis of Cu3(BTC)2/cellulose acetate mixed matrix membranes and their catalytic applications in continuous flow process

Metal-organic framework (MOF)-based mixed matrix membranes (MMMs) were fabricated by a combination of Cu3(BTC)2 MOF and polymer cellulose acetate. The cellulose acetate in the MMMs served as the matrix and the Cu3(BTC)2 MOF as the filler. The as-synthesized MMMs were utilized as a heterogeneous catalyst for aldehyde acetalization. The characterization techniques indicated that the Cu3(BTC)2 crystals were uniformly dispersed in the MMMs. The BET surface area of the Cu3(BTC)2-based MMM was measured to be 459 m2 g-1 at 60 wt% Cu3(BTC)2 loading. Furthermore, the MMMs served as an excellent catalyst under our continuous flow catalytic reaction conditions. The optimal catalytic result of benzaldehyde yield reached 94% with 60 wt% Cu3(BTC)2 loading of the MMMs at room temperature and the benzaldehyde diethyl acetal reached 0.59 mmol min-1 gCu-BTC-1.

Development of a novel Br?nsted acid UiO-66 metal-organic framework catalyst by postsynthetic modification and its application in catalysis

A novel Br?nsted acid derived metal-organic framework (MOF) has been developed to serve as an efficient heterogeneous catalyst for the acetalization and Morita-Baylis-Hillman reaction. Aromatic sulfonic acid groups were successfully incorporated to the framework of UiO-66 by post-synthetic modifications using commercially available anhydridic reagents. The UiO-66-RArSO3H Br?nsted acid catalyst was fully characterized using SEM, PXRD, FTIR, TGA and N2 adsorption/desorption isotherms. Furthermore, efficient acetalization and Morita-Baylis-Hillman reactions were evaluated to demonstrate the high catalytic performance of the UiO-66-RArSO3H catalyst. The UiO-66-RArSO3H catalyst is compatible with a variety of substituted substrates and can be recycled five times without a compromise in the yield or selectivity.

Merging metal-organic framework catalysis with organocatalysis: A thiourea functionalized heterogeneous catalyst at the nanoscale

A new thiourea-containing metal-organic framework (MOF) catalyst was synthesized. It overcomes recycling, self-aggregation and solvation issues that exist in homogeneous thiourea catalysts. Nanomorphology was introduced to increase the dispersion of the solid catalyst in solvent. Acetalization and Morita-Baylis-Hillman reactions were catalyzed using the new thiourea MOF catalyst. This journal is the Partner Organisations 2014.

Development of a SO3H-functionalized UIO-66 metal-organic framework by postsynthetic modification and studies of its catalytic activities

A novel metal-organic framework UiO-66-NH2-derived Br?nsted acid catalyst was synthesized on a gram scale by employing a postsynthetic modification strategy under mild conditions. The nanomorphology of the catalyst was designed and developed to enhance its catalytic performance. Acetalization and benzimidazole formation were evaluated to demonstrate the high reactivity and selectivity of the nanoscaled UiO-66-NH-RSO3H catalyst, which were found to be comparable to the reactivity and selectivity of the strong homogeneous Br?nsted acid catalyst. Furthermore, the UiO-66-NH-RSO3H catalyst was recycled several times without compromising the yield and selectivity. A novel metal-organic framework UiO-66-NH2-derived Br?nsted acid catalyst is synthesized by employing a postsynthetic modification strategy under mild conditions. Acetalization and benzimidazole formation are evaluated to demonstrate the high reactivity and selectivity of the nanoscaled UiO-66-NH-RSO3H catalyst.

Acid-free, organocatalytic acetalization

The acid-free, organocatalytic acetalization of various aldehydes and ketones with N,N′-bis[3,5-bis(trifluoromethyl)phenyl]thiourea is presented. The neutral, double hydrogen bonding thiourea catalyst can be used at very low loadings of 0.01-1 mol% at room temperature to furnish the respective acetals in 65-99% yield at turnover frequencies around 600 h-1. Acid-labile TBDMS-protected as well as unsaturated aldehydes can be converted efficiently into their acetals utilizing this very mild and highly practical method.

Imidazolyl compounds as inhibitors of farnesyl-protein tranferase

The present invention relates to inhibitors of ras farnesylation of Formula (I), wherein T is of Formula (1) or (2) or (3); A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, —CH2—O— or —O—CH2—; and R3—R4, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use is in cancer therapy